Other and unspecified malignant neoplasm of skin, unspecified
ICD-10 Code: C44.90 · Body Part: Head/Brain (TBI)
QME Evaluation Process
Dermatologic examination, pathology review, staging. Chapter 8 skin impairment plus disfigurement if applicable. Sun exposure documentation for outdoor workers.
Typical Impairment Rating
5-30% WPI depending on type, staging, and treatment effects
AMA Guides Edition
5th Edition
Common Treatments
Related Conditions
Body Part Guide
Head/Brain (TBI) Evaluation Guide
Impairment rating methods, common conditions, and QME evaluation protocols
QME Specialties for Other and unspecified malignant neoplasm of skin, unspecified
Find a QME Specialist
Browse QME-certified physicians who evaluate other and unspecified malignant neoplasm of skin, unspecified and related head/brain (tbi) conditions in California.
Browse Neurology Physicians →Frequently Asked Questions
What is Other and unspecified malignant neoplasm of skin, unspecified (C44.90)?
Other and unspecified malignant neoplasm of skin, unspecified is an ICD-10 diagnosis code (C44.90) classified under Skin conditions. It affects the Head/Brain (TBI) and is commonly encountered in California workers' compensation claims. QME physicians evaluate this condition using AMA Guides 5th Edition protocols.
How is C44.90 rated for impairment?
The typical whole person impairment (WPI) range for Other and unspecified malignant neoplasm of skin, unspecified is 5-30% WPI depending on type, staging, and treatment effects. The exact rating depends on clinical findings, imaging, and the evaluation method (DRE or ROM) chosen by the QME physician per AMA Guides 5th Edition.
What is the QME evaluation process for C44.90?
Dermatologic examination, pathology review, staging. Chapter 8 skin impairment plus disfigurement if applicable. Sun exposure documentation for outdoor workers.
What treatments are common for Other and unspecified malignant neoplasm of skin, unspecified?
Common treatments for Other and unspecified malignant neoplasm of skin, unspecified include Surgical excision, Mohs surgery, Radiation therapy, Chemotherapy for metastatic. Treatment appropriateness and outcomes are considered during the QME evaluation when determining permanent and stationary status and apportionment.